



**MONTHLY PROGRESS REPORT**

Name of CSE Issuer: LeenLife Pharma International Inc. (the "Issuer").

Trading Symbol: LLP

Number of Outstanding Listed Securities: 34,315,318

Date: Month of August 2017

**Report on Business**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**The Company has developed a proprietary process to manufacture omega-3 fatty acids from flax seeds. The Issuer plans to bring its proprietary omega fatty acid products to Canada and the United States. The Issuer has developed technology to combine omega fatty acids into various food products such as bread, cheese, noodles, milk, juices and chocolate.**

2. Provide a general overview and discussion of the activities of management.

**Our technology**

**The Company is currently customizing the technology for entry into the markets of Canada and the United States. This will provide the Company with proprietary technology and lower the cost of production. The Company has been focused on Poland and is preparing for entry to Canada and the United States. According to various marketing reports 50% of future world sales of omega products will be in North America, and 25% in Europe.**

**The Company had planned on building a prototype plant in Poland to test various aspects of its manufacturing process. From information gathered from visits to Poland and an analysis by our team it was decided to change course. All of the processing plants available to the Company located in Poland use a batch system of manufacturing. With batch processing great care must be taken at each processing stage to avoid oxidation (entry of air into the processing system) which causes contamination and spoilage of the product. It has been decided to use a continuous flow system where there are only two entry points of concern, the input stage and the output stage. A process has been found and tested using the necessary ingredients with positive results of a successful continuous flow system. There are numerous advantages with less handling, less manpower, better separation and better recovery of ethanol for recirculation. An excess of ethanol is necessary to obtain a better and complete reaction of the ingredients to produce the product.**

**The Company has decided to set up manufacturing facilities in the Greater Vancouver area. After a careful analysis of costs and market confidence, it was determined that the first manufacturing center should be close to the core of Company operations.**

**Collaboration with UBC**

**The Company has entered into a collaborative research agreement with the University of British Columbia to analyze some of the LeenLife products. The testing requires gas chromatography/mass spec analysis of the reaction mixtures and some analysis by liquid chromatography/mass spec for structural determination.**

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**Not applicable.**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**Not applicable.**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**Not applicable.**

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**Not applicable (other than as disclosed in Section 2 above).**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**Not applicable.**

8. Describe the acquisition of new customers or loss of customers.

**Not applicable.**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.
- Not applicable (other than as disclosed in Section 2 above).**
10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.
- Not applicable.**
11. Report on any labour disputes and resolutions of those disputes if applicable.
- Not applicable.**
12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.
- Not applicable.**
13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.
- Not applicable.**
14. Provide details of any securities issued and options or warrants granted.
- Not Applicable.**
15. Provide details of any loans to or by Related Persons.
- Not applicable.**
16. Provide details of any changes in directors, officers or committee members.
- Not applicable.**
17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The Company's primary source of funding is through the issuance of share capital. When the capital markets are depressed, the Company's activity level normally declines accordingly. As capital markets strengthen and the Company is able to secure equity financing with favorable terms, the Company's activity levels and the size and scope of planned projects will typically increase.

**Certificate Of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated September 6, 2017.

**Casey Forward**  
*Name of Director or Senior Officer*

**/s/ Casey Forward**  
*Signature*

**Director**  
*Official Capacity*

<b>Issuer Details</b> <i>Name of Issuer</i> <b>LeenLife Pharma International Inc.</b>	<i>For Month End</i> <b>August 2017</b>	<i>Date of Report</i> <i>YY/MM/DD</i> <b>17/09/06</b>
<i>Issuer Address</i> <b>Suite 380 – 580 Hornby Street</b>		
<i>City/Province/Postal Code</i> <b>Vancouver, BC, V6C 3B6</b>	<i>Issuer Fax No.</i>	<i>Issuer Telephone No.</i> <b>(778) 688-1799</b>
<i>Contact Name</i> <b>Casey Forward</b>	<i>Contact Position</i> <b>Director</b>	<i>Contact Telephone No.</i> <b>(778) 688-1799</b>
<i>Contact Email Address</i> <b>casey@caseyforward.com</b>	<i>Web Site Address</i> <b>www.leenlifepharma.com</b>	